Synapse - GDMT, Medicine

Results (1915)

Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)

Meeting Abstract

Liu, J. F.; Brady, M.; Matulonis, U. A.; Miller, A.; Kohn, E. C.; Swisher, E.; Tew, W.; Cloven, N.; Muller, C.; Bender, D.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors

Meeting Abstract

McKean, M.; Dumbrava, E. E.; Hamid, O.; Merriam, P.; Call, J. A.; Feely, W.; Green, A.; Vaishampayan, U. N.; Moore, K. N.; Weroha, S.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)

Meeting Abstract

Shapiro, G. I.; Basu, B.; El-Khoueiry, A. B.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/ KEYNOTE-775

Meeting Abstract

Colomba, E.; Lorusso, D.; Mackay, H.; Moore, R.; Yonemori, K.; Kim, Y. M.; Sanli, U. A.; Xie, R.; Barresi, G.; McKenzie, J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study

Meeting Abstract

O'Cearbhaill, R. E.; Moore, K. N.; Yeku, O.; Liu, J. F.; Bouberhan, S.; Hamilton, E. P.; Hou, J. Y.; Van Nieuwenhuysen, E.; Papadimitriou, K.; Yoo, S. Y.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation

Meeting Abstract

Dagogo-Jack, I.; Dowlati, A.; Guo, R.; Awad, M. M.; Swalduz, A.; Calvo, E.; Garcia, V. M.; Adjei, A. A.; Lorusso, P.; Punekar, S.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study

Meeting Abstract

Patel, M. R.; Doi, T.; Koyama, T.; Falchook, G. S.; Friedman, C. F.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M. M.; Mattour, A. H.; Satoh, T.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study

Meeting Abstract

Marathe, O.; Cheng, Y.; Spira, A. I.; Hamilton, E. P.; Rubinstein, M. M.; Dong, X.; Li, L.; Lv, D.; Shi, J.; Gabrail, N.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma

Meeting Abstract

Makker, V.; Lee, J. Y.; Oh, D. Y.; Oaknin, A.; Puvvada, S. D.; Cecchi, F.; McEwen, R.; Michelini, F.; Meric-Bernstam, F.
Annals of Oncology (2023)

Fulltext@MSK | Save

HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer

Journal Article

Shen, S.; Ma, W.; Brown, D.; Da Cruz Paula, A.; Zhou, Q.; Iaosonos, A.; Tessier-Cloutier, B.; Ross, D. S.; Troso-Sandoval, T.; Reis-Filho, J. S.; more...
Modern Pathology (2023)

Fulltext@MSK | Save